SeaCrest Wealth Management LLC Invests $40,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SeaCrest Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 68 shares of the biopharmaceutical company’s stock, valued at approximately $40,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Vanguard Group Inc. now owns 8,360,330 shares of the biopharmaceutical company’s stock worth $5,839,023,000 after buying an additional 201,815 shares during the last quarter. Capital World Investors increased its position in Regeneron Pharmaceuticals by 11.8% during the first quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock worth $4,155,451,000 after acquiring an additional 626,199 shares during the period. State Street Corp increased its position in Regeneron Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock worth $3,579,729,000 after acquiring an additional 325,645 shares during the period. Capital International Investors increased its position in Regeneron Pharmaceuticals by 533.0% during the first quarter. Capital International Investors now owns 1,683,899 shares of the biopharmaceutical company’s stock worth $1,176,069,000 after acquiring an additional 1,417,899 shares during the period. Finally, American Century Companies Inc. increased its position in Regeneron Pharmaceuticals by 3.5% during the first quarter. American Century Companies Inc. now owns 1,102,306 shares of the biopharmaceutical company’s stock worth $769,872,000 after acquiring an additional 37,370 shares during the period. 84.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on REGN shares. Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $655.00 to $750.00 and gave the stock a “market perform” rating in a research report on Thursday, October 20th. Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “hold” rating and boosted their price target for the company from $536.00 to $675.00 in a report on Thursday, September 8th. Canaccord Genuity Group boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company a “buy” rating in a report on Friday, September 16th. Canaccord Genuity Group boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company a “buy” rating in a report on Friday, September 16th. Finally, Raymond James lowered shares of Regeneron Pharmaceuticals from a “market perform” rating to an “underperform” rating in a report on Wednesday, October 26th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $766.81.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ REGN opened at $738.98 on Tuesday. The firm’s 50-day simple moving average is $725.69 and its 200 day simple moving average is $653.86. The company has a market cap of $80.48 billion, a price-to-earnings ratio of 15.58, a price-to-earnings-growth ratio of 2.15 and a beta of 0.20. The company has a quick ratio of 4.52, a current ratio of 5.36 and a debt-to-equity ratio of 0.13. Regeneron Pharmaceuticals, Inc. has a 12-month low of $538.01 and a 12-month high of $769.63.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Christopher R. Fenimore sold 1,844 shares of the company’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $749.00, for a total transaction of $1,381,156.00. Following the transaction, the senior vice president now directly owns 16,425 shares in the company, valued at approximately $12,302,325. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $727.82, for a total value of $727,820.00. Following the sale, the executive vice president now directly owns 19,644 shares in the company, valued at approximately $14,297,296.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christopher R. Fenimore sold 1,844 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $749.00, for a total transaction of $1,381,156.00. Following the completion of the sale, the senior vice president now owns 16,425 shares in the company, valued at $12,302,325. The disclosure for this sale can be found here. In the last three months, insiders have sold 19,993 shares of company stock worth $14,373,699. Company insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.